CNTB - CIK 0001835268
The table below shows Connect Biopharma Holdings Ltd's cash flow statement line items across its last 3 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Operating cash flow | -$51.21M | -$23.61M | -$47.74M |
| Capital expenditure | $434.00K | $750.00K | $81.00K |
| Investing cash flow | $9.82M | -$3.45M | $74.98M |
| Dividends paid | - | - | - |
| Stock buybacks | - | - | - |
| Financing cash flow | $1.09M | $227.00K | $45.00K |
Connect Biopharma Holdings Ltd reported operating cash flow of -$51.21M for fiscal year 2025. That is down 116.9% from -$23.61M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.